VHCP Management III, LLC
Follow13F filer, CIK 1738053, New York, NY
VHCP Management III, LLC reported $503,631,000 across 18 holdings for the quarter ended 2019-12-31, in a 13F-HR filed 2020-02-13. Its ten largest share positions make up 90.41% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-20-001882
- Period
- 2019-12-31
- Reported value
- $504M
- Holdings
- 18
- Top 10 weight
- 90.41%
- New
- 9
- Sold out
- 8
Part of the filer group Venrock Healthcare Capital Partners III, L.P.
Nimish ShahKoh Bong Y
Stakes and trades reported after 2019-12-31
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- OKUR ONKURE THERAPEUTICS INC: 13G 2,309,559 shares, 5.7% of the class, 13G filed 2026-11-20, 0001231919-26-001621Timeline
Accepted , ingested - ENTX ENTERA BIO LTD: 13G 8,861,763 shares, 5.1% of the class, 13G filed 2026-10-30, 0001738048-26-000079Timeline
Accepted , ingested - LYCA LYCIA THERAPEUTICS INC: 13G 6,850,237 shares, 11.9% of the class, 13G filed 2026-10-30, 0001738048-26-000077Timeline
Accepted , ingested - FLSC FRAZIER LIFE SCIENCES ACQ-A: 13G 700,000 shares, 9% of the class, 13G filed 2026-10-27, 0001738048-26-000075Timeline
Accepted , ingested - XFOR X4 PHARMACEUTICALS INC: 13G/A 7,644,072 shares, 7.6% of the class, 13G/A filed 2026-11-16, 0001738048-26-000100Timeline
Accepted , ingested - VOR VOR BIOPHARMA INC: 13G/A 6,443,619 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000098Timeline
Accepted , ingested - KRRO KORRO BIO INC: 13G/A 1,474,162 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000096Timeline
Accepted , ingested - JBIO JADE BIOSCIENCES INC: 13G/A 3,858,984 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000094Timeline
Accepted , ingested - HELP HELUS PHARMA INC: 13G/A 2,688,175 shares, 3.5% of the class, 13G/A filed 2026-11-16, 0001738048-26-000092Timeline
Accepted , ingested - CBIO CRESCENT BIOPHARMA INC.: 13G/A 2,228,641 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000090Timeline
Accepted , ingested - ACHV ACHIEVE LIFE SCIENCE INC: 13G/A 5,502,064 shares, 5.2% of the class, 13G/A filed 2026-11-16, 0001738048-26-000088Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| CONSTELLATION PHARMACEUTICALadded | +2,449,575 | $115M |
| RLMDnew | +767,938 | $29.9M |
| 89BIO INCnew | +958,765 | $25.2M |
| FORTY SEVEN INCnew | +516,381 | $20.3M |
| INTRA-CELLULAR THERAPIES INCnew | +575,000 | $19.7M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| RA PHARMACEUTICALS INCexited | -670,350 | -$15.9M |
| LA JOLLA PHARMACEUTICAL COexited | -1,251,898 | -$11M |
| BCRXexited | -2,708,207 | -$7.76M |
| PTGXreduced | -991,419 | -$7M |
| AXSMreduced | -63,335 | -$6.55M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q4 2019
Share positions as resolved from 13F-HR 0000950123-20-001882, largest first. % of portfolio is the value over $503,631,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| AXSMAXSOME THERAPEUTICS INC. | 1,547,994 | $160M | 31.77% | -63,335 | Timeline | ||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 2,516,242 | $119M | 23.54% | +2,449,575 | |||
| MISTMILESTONE PHARMACEUTICALS IN | 2,066,529 | $33.1M | 6.57% | 0 | Timeline | ||
| RLMDRELMADA THERAPEUTICS INC | 767,938 | $29.9M | 5.95% | new | Timeline | ||
| 89BIO INC89BIO INC | 958,765 | $25.2M | 5% | new | |||
| TXG10X GENOMICS INC | 300,000 | $22.9M | 4.54% | 0 | Timeline | ||
| FORTY SEVEN INCFORTY SEVEN INC | 516,381 | $20.3M | 4.04% | new | |||
| INTRA-CELLULAR THERAPIES INCINTRA-CELLULAR THERAPIES INC | 575,000 | $19.7M | 3.92% | new | |||
| IVERIC BIO INCIVERIC BIO INC | 1,699,797 | $14.6M | 2.9% | new | |||
| KALVKALVISTA PHARMACEUTICALS INC | 619,905 | $11M | 2.19% | -17,979 | Timeline | ||
| Adverum Biotechnologies, In…Adverum Biotechnologies, Inc. | 946,234 | $10.9M | 2.16% | new | |||
| MARINUS PHARMACEUTICALS INCMARINUS PHARMACEUTICALS INC | 5,016,164 | $10.8M | 2.15% | +2,500,000 | |||
| Mersana Therapeutics IncMersana Therapeutics Inc | 1,561,389 | $8.95M | 1.78% | new | |||
| MYOVANT SCIENCES LTDMYOVANT SCIENCES LTD | 455,255 | $7.07M | 1.4% | new | |||
| NEXTCURE INCNEXTCURE INC | 119,693 | $6.74M | 1.34% | new | |||
| ObsEva SAObsEva SA | 810,264 | $3.1M | 0.61% | -349,525 | |||
| PTGXPROTAGONIST THERAPEUTICS INC | 80,929 | $571K | 0.11% | -991,419 | Timeline | ||
| BELLEROPHON THERAPEUTICS INCBELLEROPHON THERAPEUTICS INC | 383,955 | $134K | 0.03% | -2,033,272 |
Sold out in Q4 2019
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| RA PHARMACEUTICALS INCRA PHARMACEUTICALS INC | 670,350 | $15.9M | shares |
| LA JOLLA PHARMACEUTICAL COLA JOLLA PHARMACEUTICAL CO | 1,251,898 | $11M | shares |
| BCRXBIOCRYST PHARMACEUTICALS INC | 2,708,207 | $7.76M | shares |
| TRICIDA INCTRICIDA INC | 80,348 | $2.48M | shares |
| KINIKSA PHARMACEUTICALS LTDKINIKSA PHARMACEUTICALS LTD | 277,137 | $2.36M | shares |
| RADIUS HEALTH INCRADIUS HEALTH INC | 23,131 | $596K | shares |
| YUMANITY THERAPEUTICS INCYUMANITY THERAPEUTICS INC | 221,267 | $187K | shares |
| PREVAIL THERAPEUTICS INCPREVAIL THERAPEUTICS INC | 4,408 | $54K | shares |
How Q4 2019 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-20-001882 | base | 2020-02-13 | acceptance time not in the bulk data set |
Filings
Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| Form 4 0001231919-26-001536 | Lycia Therapeutics, Inc. | 2026-11-04 | ||
| Form 4 0001231919-26-001519 | Lycia Therapeutics, Inc. | 2026-10-30 | ||
| Form 4 0001231919-26-001503 | Lycia Therapeutics, Inc. | 2026-10-27 | ||
| Form 3 0001231919-26-001493 | Lycia Therapeutics, Inc. | 2026-10-22 | ||
| 13F-HR 0000950123-20-001882 | Quarter ended 2019-12-31 | 2020-02-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-19-010838 | Quarter ended 2019-09-30 | 2019-11-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-19-007812 | Quarter ended 2019-06-30 | 2019-08-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-19-004908 | Quarter ended 2019-03-31 | 2019-05-14 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-19-001655 | Quarter ended 2018-12-31 | 2019-02-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-18-011333 | Quarter ended 2018-09-30 | 2018-11-13 | acceptance time not in the bulk data set |